Product Introduction
Bioactivity


英文名: Navarixin

描述: Navarixin (MK-7123) 是一种可口服的 CXCR1和 CXCR2变构拮抗剂，对猕猴 CXCR1的 Kd 值为 41 nM，对大小鼠和猕猴 CXCR2的 Kd 值分别为 0.20、0.20 和 0.08 nM。

体外活性: Navarixin is a potent, allosteric antagonist of both CXCR1 and CXCR2, with Kd values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 50 mg/mL (125.81 mM)


关键字: inhibit | MK 7123 | CXC chemokine receptors | Navarixin | Inhibitor | MK7123 | SCH527123 | CXCR | SCH-527123

相关产品: (+/-)-Vestitol | Ulocuplumab | CXCR2-IN-1 | SRT3190 | Ac-Pro-Gly-Pro-OH | SB225002 | LY2510924 acetate(1088715-84-7 free base) | AMG 487 | VUF11207 fumarate | Artemotil

相关库: Drug Repurposing Compound Library | ReFRAME Related Library | Cytokine Inhibitor Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | GPCR Compound Library | Anti-Cancer Clinical Compound Library | Inhibitor Library | Anti-Cancer Active Compound Library | Autophagy Compound Library